TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06751485: A Randomized, Open-Label, Parallel-Controlled, Multi-center Phase Ⅲ Study of JSKN003 Versus Investigator-Choice Chemotherapy for Platinum-Resistant, Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Canc

Sponsor: Jiangsu Alphamab Biopharmaceuticals Co., Ltd · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 430 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$20,993,280

Rescue Site Savings

+$13,842,444

Unlock Full NCT06751485 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06751485 Rescue Dossier →